Status:
COMPLETED
Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.
Lead Sponsor:
AstraZeneca
Conditions:
Neoplasms
Metastatic Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to determine if AZD8931 can be safely administered in Japanese patients alone and in combination with weekly paclitaxel. The study will be conducted in two parts: a m...
Eligibility Criteria
Inclusion
- Cancer that is refractory to standard therapies, or for which no standard therapies exist (monotherapy part)
- Patients suitable for Paclitaxel chemotherapy, who are not candidates for hormonal and anthracycline therapy (combination part)
- Life expectancy more than 12 weeks
Exclusion
- Inadequate kidney, liver, heart, gastric, lung or eye function
- Brain metastases
- Hypersensitive to paclitaxel (combination part)
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01003158
Start Date
October 1 2009
End Date
April 1 2012
Last Update
July 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Osaka, Japan